TBPH - Theravance Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Theravance Biopharma, Inc.

Ugland House
South Church Street PO Box 309
George Town KY1-1104
Cayman Islands
650-808-6000
http://www.theravance.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees363

Key Executives

NameTitlePayExercisedYear Born
Mr. Rick E. WinninghamChairman & CEO1.73MN/A1960
Mr. Bradford J. ShaferExec. VP, Gen. Counsel & Sec.868.58kN/A1960
Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A.Sr. VP of Corp. Devel. & StrategyN/AN/A1973
Dr. Brett K. HaumannSr. VP of Clinical Devel. & Chief Medical Officer1.26MN/A1970
Mr. Andrew Asa HindmanSr. VP & CFON/AN/A1973
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders. The company's product candidates also comprise Selective 5-HT4 Agonist for treating gastrointestinal motility disorders; Gut-selective Pan-Janus Kinase Inhibitor Program for treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TD-0714 and Neprilysin Inhibitor Program, which have completed Phase I clinical studies for heart failure and chronic kidney disease, including diabetic nephropathy. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.

Corporate Governance

Theravance Biopharma, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.